Guselkumab induction therapy results in molecular resolution of inflammation in moderately. to severely active ulcerative colitis: Results from the Phase 3 QUASAR induction study

Sunan Sridhar,¹ Amy Hart,¹ Swati Venkat,¹ Kuan-Hsiang Gary Huang,¹ Shadi Yarandi,¹ Matthew Germinaro,¹ Marion L. Vetter,¹ David Rubin,² Axel Dignass,³ Daniel Cua,¹ Tom Freeman,¹ Dawn Waterworth,¹ Bradford McRae,¹ Bram Verstockt,⁴ and Patrick Branigan,¹] anssen Research & Development LLC, Spring House, PA, USA; ³Department of Gastroenterology, University Hospitals Leuven; and Translational Research in Gastrointestinal Disorders, Department of Chronic Disease Center, Chicago, IL, USA; ³Department of Redicine I, Agaplesion Markus Hospitals Leuven; and Translational Research in Gastroenterology, University Hospitals Leuven; and Translational Research in Gastrointestinal Disorders, Department of Chronic Disease Metabolism, Leuven, Belgium

Background

Guselkumab (GUS) is a selective dual-acting IL-23p19 subunit inhibitor that potently neutralizes interleukin 23 (IL-23) and binds to \mathbf{T} CD64, a receptor on cells that produce IL-23¹ that is now approved in the United States for treatment of moderately to severely active ulcerative colitis (UC).

GUS has demonstrated efficacy in UC based on the results of the QUASAR Phase 2b/3 studies^{2,3}.

Mechanistic data from the Phase 2b induction study demonstrated a restoration of intestinal homeostasis and initiation of epithelial = repair associated with clinical response to guselkumab4. These findings were examined in the larger Phase 3 QUASAR induction study presented here

Objectives

To validate mechanistic observations from QUASAR Ph2b induction and to further characterize molecular changes induced by guselkumab treatment with the larger Ph3 QUASAR induction study.


et al. OP23 Guselkumab induction restores intestinal immune homeostasis and promotes epithelial repair in moderately to severely active Ulcerative Colitis. Journal of Crohn's and Colitis. 2024;18(Supplement_1);i41-i41s

Results

QUASAR Phase 3 induction study: Guselkumab induction therapy was effective versus placebo in patients with UC

upregulation of healthy epithelium signals at WK12


Target Patient Population: Adults with moderately to severely active UC, defined as induction baseline modified Mayo score of 5 to 9 with a Mayo rectal bleeding subscore \geq 1 and a Mayo endoscopic subscore \geq 2 based on central review



Significantly higher proportions of patients treated with GUS 200mg IV achieved primary and major secondary clinical endpoints at WK12 compared with PBO³

Clinical remission: A Mayo stool frequency subscore of 0 or 1 and not increased from baseline, a Mayo rectal bleeding subscore of 0, and a Mayo endoscopic subscore of 0, or 1 with no friability **Clinical response:** A decrease from induction baseline in the modified Mayo score by \geq 30% and \geq 2 points, with either a \geq 1-point decrease from baseline in the rectal bleeding subscore or a rectal bleeding

Differential expression of transcriptional gene modules representing cell type specific biology




Change in transcriptional gene module score (WK12 relative to WK0)

Differential expression of transcriptional gene modules representing cell type specific biology in guselkumab (GUS) treated patients. Y-axis: significance (-log10(Adj.P-value)); X-axis: change in transcriptional gene module score (gene set variation analysis (GSVA) score) (WK12-WK0)


n/N= number of patients

subscore of 0 or 1



Guselkumab induction therapy resulted in transcriptional downregulation of inflammatory signals and

Tissue Transcriptomics





Patients who achieved HEMI at WK12 demonstrated the most robust changes in transcriptional gene module expression nearing non-IBD control levels

Transcriptional gene modules changes at WK12 correlated with changes observed in the Phase 2b induction study

grading system) and endoscopic improvement

Log fold change in serum proteins (WK4 and WK12 vs WK0)

Su1979

Key Takeaways

Guselkumab treatment resulted in a global reduction in tissue inflammation and establishment of a pro-healing environment confirming the mechanistic findings of the Phase 2b induction study

Guselkumab's early clinical efficacy is reflected by serum proteomic changes that is consistent between the Phase 3 and Phase 2b induction studies

These molecular changes were closely correlated with the clinically relevant endpoints such as histoendoscopic mucosal improvement illustrating mechanisms underlying clinical efficacy outcomes

Inflammatory serum protein changes correlated with changes observed in the Phase 2b induction study